First Patient Enrolled in Regeneron Pharmaceuticals, Inc. And Bayer HealthCare AG VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion; Regeneron Received $20 Million Milestone Payment
Published: Jul 24, 2009
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the first patient has been enrolled in the Phase 3 program of VEGF Trap-Eye for the treatment of central retinal vein occlusion (CRVO), a leading cause of blindness in adults. Regeneron received a $20 million milestone payment from Bayer Healthcare that was triggered by the dosing of the first patient in the CRVO program. Regeneron also announced that enrollment in the Phase 2 DA VINCI study of VEGF Trap-Eye in diabetic macular edema (DME) has been completed and data are expected during the first half of 2010.